SAN DIEGO – Incyte Corp.'s Jakafi (ruxolitinib), already approved for treating myelofibrosis (MF), polycythemia vera and thrombocythemia MF, could soon add steroid-refractory acute graft-vs.-host disease (GVHD) to its list of FDA-approved indications. If an upcoming FDA decision goes its way, it would be the first drug approved for acute GVHD in the U.S. The review, based on the phase II Reach1 study, is expected to yield a decision by Feb. 24.